Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAAP NASDAQ:AEHAW NASDAQ:NEXI NASDAQ:NTHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAAPAdvanced Accelerator Applications$81.63$0.00$35.11▼$82.74N/AN/AN/AN/AAEHAWAesther Healthcare Acquisition$0.00$0.01$0.06▼$0.33N/AN/A34,287 shsN/ANEXINexImmune$0.00$0.00$0.00▼$1.18N/A2.046,143 shsN/ANTHINeonc Technologies$5.12-1.3%$4.98$3.20▼$25.00N/AN/A161,735 shs66,372 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAAPAdvanced Accelerator Applications0.00%0.00%0.00%0.00%0.00%AEHAWAesther Healthcare Acquisition0.00%-60.20%+50.00%+30.00%-87.42%NEXINexImmune0.00%0.00%+100.00%+100.00%-99.98%NTHINeonc Technologies0.00%+6.89%+16.10%-31.64%+511,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAAPAdvanced Accelerator ApplicationsN/AN/AN/AN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAAPAdvanced Accelerator Applications 0.00N/AN/AN/AAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAAPAdvanced Accelerator ApplicationsN/AN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAAPAdvanced Accelerator ApplicationsN/AN/A0.00∞N/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/A∞N/AN/A-534.32%-213.72%N/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAAPAdvanced Accelerator ApplicationsN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAAPAdvanced Accelerator ApplicationsN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/ANEXINexImmuneN/A0.660.66NTHINeonc TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAAPAdvanced Accelerator ApplicationsN/AAEHAWAesther Healthcare AcquisitionN/ANEXINexImmune9.85%NTHINeonc TechnologiesN/AInsider OwnershipCompanyInsider OwnershipAAAPAdvanced Accelerator ApplicationsN/AAEHAWAesther Healthcare AcquisitionN/ANEXINexImmune14.90%NTHINeonc TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAAPAdvanced Accelerator ApplicationsN/AN/AN/ANot OptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableNEXINexImmune61.40 million1.19 millionNot OptionableNTHINeonc Technologies8N/AN/AN/AAAAP, AEHAW, NTHI, and NEXI HeadlinesRecent News About These CompaniesNew to The Street’s Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 14 at 2:47 AM | freep.comFNeOnc Technologies Expands with NuroMENA Holdings IncorporationAugust 14 at 2:47 AM | msn.comNew to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 11, 2025 | eagletribune.comENeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 11, 2025 | globenewswire.comNeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and LeukemiaAugust 7, 2025 | globenewswire.comNTHI - NeOnc Technologies Holdings Inc Financials | MorningstarAugust 6, 2025 | morningstar.comMNeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain CancerAugust 4, 2025 | globenewswire.comNeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of DirectorsJuly 30, 2025 | globenewswire.comNeOnc Technologies Holdings, Inc.: NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finanznachrichten.deNeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finance.yahoo.comAI and biotech take on brain cancerJuly 30, 2025 | finance.yahoo.comNeOnc Technologies to Participate at the BTIG Virtual Biotechnology ConferenceJuly 28, 2025 | tmcnet.comNeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar InvestmentJuly 24, 2025 | finance.yahoo.comNeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on ...July 24, 2025 | bakersfield.comBCORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.July 23, 2025 | globenewswire.comNeOnc Technologies Secures Board Approval for $50 Million Strategic ...July 12, 2025 | seekingalpha.comNeOnc Technologies Holdings, Inc. Secures Board Approval for ... - NasdaqJuly 12, 2025 | nasdaq.comNeOnc Technologies Announces UAE Investment PartnershipJuly 11, 2025 | msn.comNeOnc Technologies Holdings Inc. (NTHI) Stock Price Today - WSJJuly 10, 2025 | wsj.comNeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar InvestmentJuly 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAAP, AEHAW, NTHI, and NEXI Company DescriptionsAdvanced Accelerator Applications NASDAQ:AAAPAdvanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.Aesther Healthcare Acquisition NASDAQ:AEHAW$0.0039 0.00 (0.00%) As of 08/15/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.NexImmune NASDAQ:NEXI$0.0002 0.00 (0.00%) As of 08/15/2025NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Neonc Technologies NASDAQ:NTHI$5.12 -0.07 (-1.35%) As of 08/15/2025 03:59 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access